- ICH GCP
- US Clinical Trials Registry
- Search trials
Clinical Trials on ER-positive Breast Cancer in Germany
Total 553 results
-
European Organisation for Research and Treatment...Breast International Group; Menarini GroupRecruitingStage IIB Breast Cancer | ER-positive Breast Cancer | HER2-negative Breast Cancer | Stage III Breast CancerBelgium, Italy, Ireland, France, Germany
-
AstraZenecaActive, not recruitingAdvanced ER-Positive HER2-Negative Breast CancerUnited States, Italy, Spain, Belgium, Poland, Canada, Germany, Korea, Republic of, Russian Federation, France, Israel, Hungary, Portugal, United Kingdom, Georgia, Ukraine
-
AstraZenecaActive, not recruitingER-Positive HER2-Negative Breast CancerAustria, Belgium, France, Germany, Italy, United Kingdom, United States, Canada, India, Taiwan, Russian Federation, Korea, Republic of, Hungary, Japan, Mexico, Turkey, China, Malaysia, Spain, Czechia, Portugal, Poland, Norway, Bulgaria, Slovaki... and more
-
AstraZenecaRecruitingER-Positive HER2-Negative Breast CancerUnited States, Israel, Spain, Korea, Republic of, Italy, Poland, Belgium, Norway, Bulgaria, France, Germany, United Kingdom, Japan, Taiwan, Canada, Hungary, Australia, Austria, Portugal, Turkey, Russian Federation, Slovakia, Switzer...
-
Genentech, Inc.RecruitingEstrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast CancerKorea, Republic of, United States, Spain, Taiwan, United Kingdom, Japan, Germany, Argentina, Turkey, Greece, Italy, Singapore, South Africa
-
Novartis PharmaceuticalsTerminatedAdvanced or Metastatic ER+ Breast CancerUnited States, France, Germany, Singapore, Italy, Japan, Belgium
-
AstraZenecaCompletedPostmenopausal Women With ER+ HER2- Primary Breast CancerGermany, United Kingdom
-
Hoffmann-La RocheTerminatedEstrogen Receptor-positive (ER+)/Human Epidermal Growth Factor Receptor (HER2)-Negative Locally Advanced or Metastatic Breast CancerCanada, United States, United Kingdom, Australia, Germany
-
AstraZenecaCompletedFGFR Inhibition, Pharmacokinetics, Biomarkers | ER+ Breast CancerCzech Republic, Italy, United Kingdom, Hungary, Germany, Romania, Belgium, France
-
Queen Mary University of LondonAstellas Pharma IncUnknownPrimary Breast Cancer ER+ve | Primary Breast Cancer AR+ve TNBNGermany, United Kingdom, Spain, United States, Ireland
-
Kliniken Essen-MitteRecruitingBreast Cancer | Node-positive Breast CancerGermany
-
German Breast GroupBoehringer IngelheimCompleted
-
German Breast GroupRoche Pharma AGRecruitingHER2-positive Breast CancerGermany
-
Institut fuer FrauengesundheitNovartis Pharmaceuticals; AGO Breast Study Group e.V.RecruitingBreast Cancer | Hormone Receptor Positive Breast Carcinoma | HER2-negative Breast CancerGermany
-
University Hospital TuebingenUniversity Hospital Freiburg; University Hospital UlmRecruitingHormone Receptor Positive HER-2 Negative Breast CancerGermany
-
iOMEDICO AGAmgen; Arbeitsgemeinschaft fur Internistische OnkologieWithdrawnAdvanced Breast Cancer | HER2-positive Breast CancerGermany
-
iOMEDICO AGSeagen Inc.RecruitingHER2-positive Breast CancerGermany, Austria
-
BioInvent International ABActive, not recruitingHER2-positive Breast Cancer | HER2-positive Gastric Cancer | Metastatic Gastric Adenocarcinoma | Metastatic Gastroesophageal Junction Adenocarcinoma | HER2-positive Metastatic Breast CancerSpain, United Kingdom, Germany
-
German Breast GroupGlaxoSmithKline; Stemline Therapeutics, Inc.Not yet recruitingBRCA1 Mutation | BRCA2 Mutation | PALB2 Gene Mutation | Hormone Receptor Positive HER-2 Negative Breast Cancer | Advanced or Metastatic Breast CancerGermany
-
German Breast GroupCelgene Corporation; AmgenCompletedInflammatory Breast Cancer | HER2 Positive Breast Cancer | Tubular Breast Cancer Stage II | Mucinous Breast Cancer Stage II | Breast Cancer Female NOS | Invasive Ductal Breast Cancer | Tubular Breast Cancer Stage IIIGermany
-
German Breast GroupRoche Pharma AG; Celgene CorporationCompletedInflammatory Breast Cancer | HER-2 Positive Breast Cancer | Tubular Breast Cancer Stage II | Mucinous Breast Cancer Stage II | Breast Cancer Female NOS | Invasive Ductal Breast Cancer | Tubular Breast Cancer Stage III | Inflammatory Breast Cancer Stage IVGermany
-
Institut fuer FrauengesundheitSamsung Bioepis Co., Ltd.RecruitingBreast Cancer | Breast Neoplasms | HER2-positive Breast Cancer | Breast Cancer FemaleGermany
-
German Breast GroupRoche Pharma AG; Amgen; Teva Pharmaceuticals USA; Vifor PharmaCompletedInflammatory Breast Cancer | HER2 Positive Breast Cancer | Tubular Breast Cancer Stage II | Mucinous Breast Cancer Stage II | Breast Cancer Female NOS | Invasive Ductal Breast Cancer | Tubular Breast Cancer Stage IIIGermany
-
Novartis PharmaceuticalsBreast International Group; German Breast Group; SOLTI Breast Cancer Research...CompletedHER2-positive Newly Diagnosed, Primary Breast CancerAustria, Spain, Australia, Germany
-
Alliance Foundation Trials, LLC.Pfizer; Syneos Health; UNICANCER; German Breast Group; SOLTI Breast Cancer Research... and other collaboratorsActive, not recruitingHER-2 Positive Breast Cancer | Estrogen Receptor Positive Breast CancerUnited States, Spain, France, Italy, Germany, Australia, Portugal, New Zealand
-
Eli Lilly and CompanyCompletedHER-2 Positive Breast Cancer | Hormone Receptor Positive Breast CancerSpain, United States, Korea, Republic of, Belgium, France, Germany, Italy, Australia, Argentina, Canada, United Kingdom, Mexico, Brazil, Greece
-
German Breast GroupGlaxoSmithKline; Roche Pharma AG; Teva Pharmaceuticals USACompletedInflammatory Breast Cancer | HER-2 Positive Breast Cancer | Tubular Breast Cancer Stage II | Mucinous Breast Cancer Stage II | Breast Cancer Female NOS | Invasive Ductal Breast Cancer | Tubular Breast Cancer Stage III | Inflammatory Breast Cancer Stage IVGermany
-
West German Study GroupAstraZenecaNot yet recruitingHER2-positive Early Breast CancerGermany
-
CinnagenCompletedHER2-positive Breast CancerIran, Islamic Republic of
-
iOMEDICO AGNovartis Pharmaceuticals; Arbeitsgemeinschaft fur Internistische OnkologieCompletedBreast Cancer Recurrent | HER2/Neu-negative Carcinoma of Breast | Hormone Receptor Positive Malignant Neoplasm of BreastGermany
-
Novartis PharmaceuticalsCompletedAdvanced HER2-positive Breast CancerFrance, Italy, Germany, Singapore, Sweden, Spain, United Kingdom, United States
-
Prof. W. JanniCompletedHER2-negative Metastatic Breast Cancer | HER2-positive Circulating Tumor CellsGermany
-
Institut fuer FrauengesundheitNovartis Pharmaceuticals; AGO Breast Study Group e.V.RecruitingBreast Cancer | Breast Neoplasms | Advanced Breast Cancer | Breast Neoplasm Female | Breast Cancer Female | HER2-negative Breast Cancer | Hormone Receptor-positive Breast CancerGermany
-
University Hospital, Basel, SwitzerlandETOP IBCSG Partners Foundation; Austrian Breast Cancer Study GroupRecruitingNode-positive Breast CancerGreece, Switzerland, Hungary, Austria, Germany, Italy, Lithuania, Argentina, Croatia
-
Prof. Wolfgang JanniEli Lilly and CompanyRecruitingHormone Receptor-positive Metastatic Breast Cancer | HER2-negative Metastatic Breast CancerGermany, Switzerland
-
Novartis PharmaceuticalsCompletedMetastatic Colorectal Cancer | Gastric Cancer | Advanced Solid Tumors | Metastatic Breast Cancer | Gastroesophageal Junction Cancer | Recurrent Glioblastoma Multiforme | Advanced Pancreatic Adenocarcinoma | Safety | Triple Negative Metastatic Breast Cancer | Dose Escalation | Preliminary Efficacy | Hormone Receptor...Canada, United Kingdom, Spain, Germany, Italy, Belgium, Australia, United States
-
Prof. W. JanniActive, not recruitingHER2-negative and Hormone-receptor Positive Metastatic Breast Cancer | HER2-negative Circulating Tumor Cells | Postmenopausal Female PatientsGermany
-
Queen Mary University of LondonAstraZenecaUnknownEstrogen Receptor Positive Breast CancerSpain, United Kingdom, France, Portugal, Georgia, Korea, Republic of, Germany, Hungary, Romania
-
Novartis PharmaceuticalsCompletedEstrogen Receptor Positive Breast Cancer | Advanced Solid Tumors With an Alteration of the PIK3CA GeneUnited States, Netherlands, Spain, Germany, United Kingdom
-
Sponsor GmbHGlaxoSmithKline; iOMEDICO AG; Arbeitsgemeinschaft fur Internistische Onkologie; Arbeitskreis Klinische StudienTerminatedMetastatic Breast Cancer | HER2 Positive | First or Second Line Therapy | Failure or Contraindication of Trastuzumab TherapyGermany
-
German Breast GroupNovartisCompletedBreast Cancer | Hormone Receptor Positive TumorGermany
-
iOMEDICO AGNovartis PharmaceuticalsCompletedBreast Cancer | Hormone Receptor Positive Tumor | HER 2 Negative Breast CancerGermany
-
Merrimack PharmaceuticalsTerminatedBreast Cancer | HER2 Positive Breast CancerSpain, United States, Italy, France, Canada, Belgium, Austria, Germany, Czech Republic
-
AstraZenecaDaiichi SankyoActive, not recruitingBreast Cancer | Breast Neoplasms | HER2-positive Early Breast CancerUnited States, Italy, Spain, Poland, Taiwan, Thailand, Canada, Germany, Korea, Republic of, Brazil, India, Japan, Peru, Philippines, China, Saudi Arabia, Russian Federation, Bulgaria
-
Seagen Inc.Merck Sharp & Dohme LLCRecruitingHER2 Positive Breast CancerUnited States, Taiwan, Canada, Korea, Republic of, Austria, China, Spain, Japan, France, Italy, Switzerland, Australia, Belgium, Brazil, Germany, Portugal, United Kingdom, Netherlands, Czechia, Greece, Chile, Finland, Poland
-
AstraZenecaDaiichi SankyoActive, not recruitingBreast Cancer; HER2-positive; MetastaticUnited States, Belgium, Canada, Denmark, Italy, Spain, Hungary, Taiwan, Turkey, France, Germany, Korea, Republic of, Brazil, India, Japan, Peru, Philippines, United Kingdom, China, South Africa, Israel, Russian Federation, Argentina, ... and more
-
MedSIRPfizerCompletedBreast Cancer | Advanced Breast Cancer | Hormone Receptor Positive Tumor | Human Epidermal Growth Factor 2 Negative Carcinoma of BreastSpain, Germany, France, United Kingdom, Italy, Slovenia
-
Seagen Inc.RecruitingHER2-positive Breast CancerUnited States, Australia, Austria, Belgium, Canada, China, Denmark, France, Germany, Israel, Italy, Japan, Korea, Republic of, Netherlands, Singapore, Spain, Sweden, Switzerland, Taiwan, United Kingdom
-
Daiichi Sankyo, Inc.AstraZeneca; NSABP Foundation Inc; German Breast Group; Spanish Breast Cancer Research...Active, not recruitingHER2-Positive Primary Breast Cancer | Residual Invasive Breast CancerUnited States, Spain, France, Germany, Korea, Republic of, United Kingdom, Denmark, Israel, Belgium, Taiwan, Chile, Italy, Japan, Peru, Portugal, China, Turkey, Canada, Ireland, Australia, Greece, Czechia, Singapore, Poland, Romania, Arge... and more
-
Palleos Healthcare GmbHRoche Pharma AG; University Hospital, Essen; University Hospital Erlangen; Phaon...Active, not recruitingTriple-negative Breast CancerGermany